<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Shigella infection: Treatment and prevention in children
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Shigella infection: Treatment and prevention in children
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Shigella infection: Treatment and prevention in children
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shai Ashkenazi, MD, MSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheldon L Kaplan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Diane Blake, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Shigella
         </em>
         infections are a major cause of pediatric morbidity and mortality worldwide.
        </p>
        <p>
         <em>
          Shigella
         </em>
         infection is characterized by high fever (&gt;38.5°C [101.3°F]), abdominal cramps, diarrhea, tenesmus, and polymorphonuclear leukocytes on a
         <a class="drug drug_pediatric" data-topicid="12599" href="/z/d/drug information/12599.html" rel="external">
          methylene blue
         </a>
         stain of the stool; extraintestinal manifestations and complications also occur (
         <a class="graphic graphic_table graphicRef69134" href="/z/d/graphic/69134.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ]. Definitive diagnosis requires a stool culture or a polymerase chain reaction assay. The characteristic small-volume, bloody/mucous stools are present in approximately one-half of the children with shigellosis [
         <a href="#rid1">
          1
         </a>
         ]. Neonates [
         <a href="#rid3">
          3
         </a>
         ] and children with underlying immune deficiency (including human immunodeficiency virus [HIV] infection) [
         <a href="#rid4">
          4,5
         </a>
         ] or malnutrition [
         <a href="#rid6">
          6,7
         </a>
         ] are at increased risk of bacteremia and other complications of shigellosis. (See
         <a class="medical medical_review" href="/z/d/html/2718.html" rel="external">
          "Shigella infection: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
         The treatment of and prevention of
         <em>
          Shigella
         </em>
         infection in children will be reviewed here. The microbiology, epidemiology, pathogenesis, clinical manifestations, and diagnosis of
         <em>
          Shigella
         </em>
         infection in children are discussed separately, as is the treatment of
         <em>
          Shigella
         </em>
         in adults. (See
         <a class="medical medical_review" href="/z/d/html/2718.html" rel="external">
          "Shigella infection: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2701.html" rel="external">
          "Shigella infection: Treatment and prevention in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H583353163">
         <span class="h1">
          NATURAL HISTORY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infection with
         <em>
          Shigella
         </em>
         generally is self-limited; the average duration of gastrointestinal symptoms in untreated
         <em>
          Shigella
         </em>
         gastroenteritis is approximately seven days [
         <a href="#rid8">
          8
         </a>
         ]. In the absence of specific antibiotic treatment, children with
         <em>
          Shigella
         </em>
         gastroenteritis shed the organism for up to four weeks; children with immune deficiency shed for much longer periods, even if their symptoms have resolved [
         <a href="#rid1">
          1,4,5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          SUPPORTIVE THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Correction of fluid and electrolyte losses is the mainstay of treatment of acute gastroenteritis in children, no matter the cause [
         <a href="#rid1">
          1
         </a>
         ]. Oral rehydration is preferred when feasible [
         <a href="#rid9">
          9
         </a>
         ], but intravenous fluids may be necessary. Fluid repletion in children is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6129.html" rel="external">
          "Oral rehydration therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6103.html" rel="external">
          "Treatment of hypovolemia (dehydration) in children in resource-abundant settings"
         </a>
         .)
        </p>
        <p>
         Early restoration of oral intake, especially protein, is important to prevent malnutrition, particularly in resource-limited countries [
         <a href="#rid10">
          10-12
         </a>
         ]. In addition, the administration of
         <a class="drug drug_pediatric" data-topicid="12883" href="/z/d/drug information/12883.html" rel="external">
          vitamin A
         </a>
         or zinc, or the ingestion of unripe, mature green banana fruit, may hasten resolution of symptoms in malnourished children in resource-limited countries [
         <a href="#rid13">
          13-17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13956.html" rel="external">
          "Approach to the child with acute diarrhea in resource-limited settings", section on 'Vitamins and minerals'
         </a>
         .)
        </p>
        <p>
         Intestinal antimotility drugs (eg,
         <a class="drug drug_pediatric" data-topicid="12679" href="/z/d/drug information/12679.html" rel="external">
          paregoric
         </a>
         , diphenoxylate,
         <a class="drug drug_pediatric" data-topicid="12561" href="/z/d/drug information/12561.html" rel="external">
          loperamide
         </a>
         ) should be avoided in children with suspected shigellosis [
         <a href="#rid18">
          18
         </a>
         ]. These drugs may prolong the duration of fever, diarrhea, and excretion of the organism [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          ANTIBIOTIC RESISTANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibiotic susceptibility testing is essential for management of patients with suspected
         <em>
          Shigella
         </em>
         infection. Antimicrobial resistance is relatively high and patterns of resistance vary geographically [
         <a href="#rid20">
          20-23
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          In the United States
         </strong>
         – In the United States, antimicrobial resistance is an increasing problem. Among the 3079
         <em>
          Shigella
         </em>
         isolates tested by the National Antimicrobial Resistance Monitoring System (NARMS) for Enteric Bacteria by whole genome sequencing during 2022, the following results were reported [
         <a href="#rid23">
          23
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          Ceftriaxone
         </a>
         – 10.9 percent resistant
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">
          Ciprofloxacin
         </a>
         – 54.3 percent had decreased susceptibility
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          Azithromycin
         </a>
         – 32.1 percent resistant
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          Ampicillin
         </a>
         – 67.8 percent resistant
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">
          Trimethoprim-sulfamethoxazole
         </a>
         – 63.3 percent resistant
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nalidixic acid – 31.8 percent resistant
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In 2022, 89.1 percent of isolates tested by whole genome sequencing were resistant to ≥3 Clinical and Laboratory Standards Institute antimicrobial classes [
         <a href="#rid23">
          23
         </a>
         ], and 5 percent were extensively drug resistant (ie, resistant to
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">
          ciprofloxacin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          ampicillin
         </a>
         (compared with 0 percent in 2015) [
         <a href="#rid24">
          24
         </a>
         ]. Only 5 percent of patients with XDR Shigella isolates were children.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Risk factors for drug-resistant Shigella include international travel to or adoption from Asia or Africa [
         <a href="#rid23">
          23,25-27
         </a>
         ] and treatment with cephalosporins for
         <em>
          Shigella
         </em>
         or
         <em>
          Salmonella
         </em>
         infection [
         <a href="#rid28">
          28
         </a>
         ]. In addition, antibiotic-resistant
         <em>
          Shigella
         </em>
         infections have been observed more frequently among men who have sex with men, people with HIV infection, and people experiencing homelessness [
         <a href="#rid24">
          24,29,30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Decreased susceptibility to
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         and/or other antibiotics has also been detected in several
         <em>
          Shigella sonnei
         </em>
         and
         <em>
          Shigella flexneri
         </em>
         outbreaks and sporadic cases throughout the United States, predominantly among men who have sex with men and people experiencing homelessness [
         <a href="#rid24">
          24,29,31-35
         </a>
         ]. Scattered infections with extremely drug-resistant isolates that are ciprofloxacin-resistant and have decreased susceptibility to azithromycin have also been reported [
         <a href="#rid36">
          36,37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Species-, state-, and antibiotic-specific resistance information is available from
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwwwn.cdc.gov%2Fnarmsnow%2F&amp;token=or3eUlpzJzn0H2eHuzyjqTI0yCZkQgh5wVCwHFHyUEDhciD4A56fn0z2GkZe4dK4&amp;TOPIC_ID=6003" target="_blank">
          NARMS Now
         </a>
         , an interactive tool provided by the Centers for Disease Control and Prevention [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          In other regions
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Europe – In Europe, resistance to nalidixic acid,
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         has been reported [
         <a href="#rid38">
          38,39
         </a>
         ] but is uncommon. In a systematic review, during 2010 to 2012, &lt;1 percent of isolates from Europe-America were resistant to ceftriaxone,
         <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">
          cefotaxime
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">
          ceftazidime
         </a>
         [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         New Zealand – In a 2015 to 2016 nationwide survey of
         <em>
          Shigella
         </em>
         isolates in New Zealand, 23 percent of isolates were resistant to fluoroquinolones and 11 percent were resistant to
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Asia and Africa – In India and Bangladesh, 20 percent or more of isolates are resistant to nalidixic acid [
         <a href="#rid42">
          42-44
         </a>
         ]. Increasing levels of resistance to
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         have also been reported in Asia [
         <a href="#rid45">
          45-47
         </a>
         ]. In a systematic review, during 2010 to 2012, 14 percent of isolates from Asia-Africa were resistant to ceftriaxone, 23 percent to
         <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">
          cefotaxime
         </a>
         , and 6 percent to
         <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">
          ceftazidime
         </a>
         [
         <a href="#rid40">
          40
         </a>
         ]. Resistance to third-generation cephalosporins was especially high in Vietnam, China, and Iran.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          ANTIBIOTIC THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Rationale
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goals of antibiotic therapy for
         <em>
          Shigella
         </em>
         include improvement in symptoms and eradication of the organism, which may result in decreased spread of infection.
        </p>
        <p>
         In randomized trials, appropriate antimicrobial treatment of
         <em>
          Shigella
         </em>
         gastroenteritis improves diarrhea (by approximately three days), fever (by approximately one day) and reduces shedding (two to five days versus up to four weeks if untreated) [
         <a href="#rid48">
          48-52
         </a>
         ]. It is uncertain whether antibiotic therapy prevents relapse [
         <a href="#rid52">
          52
         </a>
         ]. Appropriate antimicrobial treatment also may reduce the risk of developing complications [
         <a href="#rid49">
          49,53
         </a>
         ]. (See
         <a class="local">
          'Natural history'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2718.html" rel="external">
          "Shigella infection: Epidemiology, clinical manifestations, and diagnosis", section on 'Intestinal complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2718.html" rel="external">
          "Shigella infection: Epidemiology, clinical manifestations, and diagnosis", section on 'Systemic complications'
         </a>
         .)
        </p>
        <p>
         These benefits outweigh the potential risk of promoting the development of resistant organisms. Serious adverse effects may occur with antibiotics used to treat
         <em>
          Shigella
         </em>
         (eg, anaphylaxis, hypersensitivity, Stevens-Johnson syndrome). However, in a 2010 meta-analysis of 16 trials (1748 pediatric and adult participants), all of the antibiotics were found to be safe; no serious adverse effects were reported. Antimicrobial therapy does not appear to increase the risk of
         <em>
          Shigella dysenteriae
         </em>
         -related hemolytic-uremic syndrome [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2718.html" rel="external">
          "Shigella infection: Epidemiology, clinical manifestations, and diagnosis", section on 'Hemolytic-uremic syndrome (HUS)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Decisions regarding initiation of antimicrobial therapy must consider the clinical condition of the patient, host factors that predispose to more severe infection, and public health considerations.
         <em>
          Shigella
         </em>
         is highly contagious – ingestion of as few as 10 organisms can produce disease [
         <a href="#rid55">
          55
         </a>
         ]. Thus, eradication of the organism from children and adolescents at risk to transmit the disease to others (eg, a daycare attendee, hospitalized patient) is particularly compelling.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunocompromised or ill patients
         </strong>
         – We recommend empiric antimicrobial therapy for shigellosis in children and adolescents who present with suspected shigellosis (eg, bloody/mucous diarrhea, abdominal cramping, high fever, polymorphonuclear leukocytes on a
         <a class="drug drug_pediatric" data-topicid="12599" href="/z/d/drug information/12599.html" rel="external">
          methylene blue
         </a>
         stain of the stool) and [
         <a href="#rid6">
          6,56
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Are immunocompromised
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Have clinical features that may suggest bacteremia (leukocytosis, hypothermia, temperature &gt;39°C [102.2°F], lethargy)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For these patients, antibiotics should be started empirically – after obtaining stool, and, if needed, also blood culture – and then modified as needed based upon susceptibility testing. (See
         <a class="local">
          'Choice of regimen'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptomatic patients with culture-proven
         </strong>
         <strong>
          <em>
           Shigella
          </em>
         </strong>
         <strong>
         </strong>
         – We recommend antimicrobial therapy for children and adolescents with symptomatic culture-proven
         <em>
          Shigella
         </em>
         who:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Have documented bacteremia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Require hospitalization
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Attend daycare
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Live in institutions
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Are involved in food handling
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For other symptomatic patients, antimicrobial therapy also may be warranted, but the decision depends upon the severity of illness and risk of transmitting infection to others.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Suspected
         </strong>
         <strong>
          <em>
           Shigella
          </em>
         </strong>
         – We suggest antimicrobial therapy for symptomatic children and adolescents who do not fall into one of the above categories and have one of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Suspected shigellosis according to epidemiologic data (eg, outbreak setting, positive culture in household or daycare contact, etc)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Suspected shigellosis on clinical basis (bloody/mucous diarrhea, high fever)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild disease or recently recovered
         </strong>
         – We do not recommend antimicrobial therapy for most children with mild disease or spontaneous recovery. We suggest antimicrobial therapy for children with mild disease or children who have recovered from
         <em>
          Shigella
         </em>
         by the time the report of positive
         <em>
          Shigella
         </em>
         culture is available if they are hospitalized, attend daycare centers, or live in institutions. However, such treatment is controversial. Antimicrobial treatment is unlikely to significantly affect the clinical course but will shorten fecal excretion and thus possibly reduce the spread of this highly contagious bacterium.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Choice of regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         The empiric antibiotic regimen is determined by host factors, severity of illness, local resistance patterns, and history of travel to an area with increased resistance [
         <a href="#rid57">
          57,58
         </a>
         ]. Empiric therapy is changed as necessary based upon the results of susceptibility testing (which should be performed on all isolates) or if the patient remains symptomatic after ≥3 days of therapy. (See
         <a class="local">
          'Antibiotic resistance'
         </a>
         above and
         <a class="local">
          'Treatment failure'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H848310686">
         <span class="h3">
          Parenteral versus oral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Parenteral antibiotic therapy is indicated for children with proven or suspected shigellosis who:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Have underlying immune deficiency; shigellosis in children with immune deficiency, including acquired immunodeficiency syndrome (AIDS), is associated with a prolonged course, increased risk of complications, and prolonged shedding
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Have severe toxemia or suspected bacteremia (signs of suspected bacteremia include leukocytosis, hypothermia, temperature &gt;39°C [102.2°F], and lethargy [
         <a href="#rid6">
          6
         </a>
         ]); bacteremia is associated with increased mortality (see
         <a class="medical medical_review" href="/z/d/html/2718.html" rel="external">
          "Shigella infection: Epidemiology, clinical manifestations, and diagnosis", section on 'Systemic complications'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Are unable to take oral medications (vomiting, stupor, etc)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H848310652">
         <span class="h3">
          Parenteral therapy
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Susceptibility results available
         </strong>
         – Children whose susceptibility testing results are available should be treated with an antibiotic to which their isolate is susceptible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Susceptibility of isolate unknown and extensively drug resistant shigellosis is not suspected
         </strong>
         – For children and adolescents with proven or suspected shigellosis, in whom the antibiotic susceptibility of the isolate is unknown and extensively drug-resistant
         <em>
          Shigella
         </em>
         is not suspected, the preferred parenteral therapy varies with age.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children &lt;18 years of age, we prefer
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         [
         <a href="#rid56">
          56
         </a>
         ]. Fluoroquinolones are an alternative for children in whom there is no other safe and effective alternative [
         <a href="#rid59">
          59
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/490.html" rel="external">
          "Fluoroquinolones", section on 'Children'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children ≥18 years of age, we prefer
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">
          ciprofloxacin
         </a>
         [
         <a href="#rid8">
          8,60,61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The regimens are as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          Ceftriaxone
         </a>
         50 mg/kg per day intravenously (IV) in a single daily dose (maximum 1.5 g) for five days.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Patients who do not have immune deficiency or bacteremia and are afebrile after two days may be treated for two rather than five days [
         <a href="#rid62">
          62
         </a>
         ]. In comparative studies, two days of
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         was as effective as five days [
         <a href="#rid62">
          62,63
         </a>
         ]. However, a single dose of ceftriaxone did not eradica
         <em>
          te Shigella
         </em>
         from the stool in adult patients [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">
          Ciprofloxacin
         </a>
         10 mg/kg IV (maximum 400 mg/dose) every 12 hours for three to five days [
         <a href="#rid8">
          8,60,61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Both
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">
          ciprofloxacin
         </a>
         achieve high concentrations in the serum and stool and have activity against
         <em>
          Shigella
         </em>
         and usually against some other bacterial causes of diarrhea (eg, ceftriaxone against
         <em>
          Salmonella;
         </em>
         ciprofloxacin against
         <em>
          Salmonella
         </em>
         and
         <em>
          Campylobacter
         </em>
         ) [
         <a href="#rid64">
          64,65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The benefits of
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         were demonstrated in an open trial in which 40 children (mean age 4.5 years) with severe
         <em>
          Shigella
         </em>
         dysentery were randomly assigned to IV ceftriaxone 50 mg/kg per day or
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          ampicillin
         </a>
         100 mg/kg per day for one to two days followed by intramuscular or oral therapy, respectively [
         <a href="#rid66">
          66
         </a>
         ]. All of the
         <em>
          Shigella
         </em>
         isolates were sensitive to ceftriaxone, whereas 28 percent were resistant to ampicillin. Children treated with ceftriaxone had shorter mean duration of diarrhea (2.5 versus 6.8 days), greater rates of eradication from the stool after five days (100 versus 60 percent), and fewer bacteriologic relapses (0 versus 40 percent) than those treated with ampicillin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Confirmed or suspected extensively drug-resistant shigellosis
         </strong>
         <strong>
          <em>
          </em>
         </strong>
         – For children with confirmed or suspected extensively drug-resistant shigellosis, consultation with an expert in infectious diseases may be warranted. Parenteral therapy options for extensively drug-resistant
         <em>
          Shigella
         </em>
         are limited. Some experts suggest intravenous carbapenem therapy (eg,
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          meropenem
         </a>
         ), although carbapenems should be reserved for children with severe
         <em>
          Shigella
         </em>
         infection or
         <em>
          Shigella
         </em>
         infection in an immunocompromised child [
         <a href="#rid67">
          67
         </a>
         ]. Extensively drug-resistant
         <em>
          Shigella
         </em>
         isolates in the United States generally do not carry resistance mechanisms for carbapenems [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Oral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral treatment of shigellosis depends upon local resistance patterns. Susceptibility testing should be performed on all isolates and empiric therapy changed as necessary based upon the results, as well as on clinical response because the breakpoints for susceptibility to
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         have not been established [
         <a href="#rid8">
          8,39,56
         </a>
         ]. Recommended doses and durations are provided in the table (
         <a class="graphic graphic_table graphicRef88651" href="/z/d/graphic/88651.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H33238857">
         <span class="h4">
          Children &lt;18 years
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preferred initial oral therapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Susceptibility results available
         </strong>
         – Children whose susceptibility testing results are available should be treated with an antibiotic to which their isolate is susceptible.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Susceptibility unknown and extensively drug-resistant shigellosis is not suspected
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          Azithromycin
         </a>
         is the preferred initial oral treatment of shigellosis in children &lt;18 years of age if the antibiotic susceptibility of the isolate is unknown and extensively drug-resista
         <em>
          nt Shigella
         </em>
         is not suspected.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In a randomized trial in hospitalized adults with shigellosis,
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         was clinically and bacteriologically successful in 82 and 94 percent of recipients, respectively [
         <a href="#rid64">
          64
         </a>
         ]. However, resistance to azithromycin is increasing in many parts of the world [
         <a href="#rid23">
          23,30,36,41,68
         </a>
         ] and in certain populations, such as adolescent men who have sex with men [
         <a href="#rid29">
          29,33
         </a>
         ]. Children and adolescents who do not respond to azithromycin may require an alternative agent, guided by susceptibility testing to other antibiotics. (See
         <a class="local">
          'Antibiotic resistance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For children who acquire shigella in South Asia (eg, India, Pakistan, Bangladesh),
         <a class="drug drug_pediatric" data-topicid="13127" href="/z/d/drug information/13127.html" rel="external">
          cefixime
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13059" href="/z/d/drug information/13059.html" rel="external">
          ceftibuten
         </a>
         may be used as the initial oral agent. In South Asia there is widespread resistance to other commonly used drugs, including
         <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">
          ciprofloxacin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Confirmed or suspected extensively drug-resistant shigellosis
         </strong>
         – For children with confirmed or suspected extensively drug-resistant shigellosis, consultation with an expert in infectious diseases may be warranted. Some experts suggest a regimen of
         <a class="drug drug_general" data-topicid="118047" href="/z/d/drug information/118047.html" rel="external">
          pivmecillinam
         </a>
         (not available in the United States) for 5 to 7 days with
         <a class="drug drug_pediatric" data-topicid="126342" href="/z/d/drug information/126342.html" rel="external">
          fosfomycin
         </a>
         on days 1, 3, and 5 [
         <a href="#rid67">
          67
         </a>
         ]. Extensively drug-resistant
         <em>
          Shigella
         </em>
         isolates in the United States generally do not carry resistance mechanisms for fosfomycin [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral therapy alternatives
         </strong>
         – Alternative oral treatment options for children &lt;18 years of age include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fluoroquinolones (eg,
         <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">
          ciprofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9710" href="/z/d/drug information/9710.html" rel="external">
          norfloxacin
         </a>
         [not available in the United States]) are an alternative to
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         ; in children &lt;18 years of age they are reserved for
         <em>
          Shigella
         </em>
         caused by isolates resistant to other oral antibiotics [
         <a href="#rid59">
          59
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/490.html" rel="external">
          "Fluoroquinolones", section on 'Children'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13127" href="/z/d/drug information/13127.html" rel="external">
          Cefixime
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13059" href="/z/d/drug information/13059.html" rel="external">
          ceftibuten
         </a>
         is an alternative to
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         [
         <a href="#rid69">
          69-71
         </a>
         ], although experience with these agents is limited and their efficacy is unclear [
         <a href="#rid56">
          56
         </a>
         ]. In an open randomized trial, azithromycin was more effective than cefixime in bacterial eradication [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nalidixic acid (not available in the United States) is an alternative in regions with low levels of resistance. However, nalidixic acid must be given four times per day. In addition, in studies in children and adults, nalidixic acid was inferior to fluoroquinolones and
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         in reducing duration of diarrhea and/or eradication of the organism from the stool [
         <a href="#rid73">
          73-76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="118047" href="/z/d/drug information/118047.html" rel="external">
          Pivmecillinam
         </a>
         (an extended spectrum penicillin, also not available in the United States) is another alternative. In randomized trials and systematic reviews, it was effective in reducing duration of diarrhea and eradication of the organism from the stool [
         <a href="#rid57">
          57,61,77
         </a>
         ]. However, pivmecillinam must be given four times per day [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">
          Trimethoprim-sulfamethoxazole
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          ampicillin
         </a>
         should be used only if the isolated strain is known to be susceptible given the high worldwide resistance.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H33238912">
         <span class="h4">
          Adolescents ≥18 years
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to the treatment of
         <em>
          Shigella
         </em>
         in adolescents ≥18 years is the same as that for adults. (See
         <a class="medical medical_review" href="/z/d/html/2701.html" rel="external">
          "Shigella infection: Treatment and prevention in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H848310421">
         <span class="h1">
          FOLLOW-UP
         </span>
        </p>
        <p class="headingAnchor" id="H672227549">
         <span class="h2">
          Treatment response
         </span>
         <span class="headingEndMark">
          —
         </span>
         Improvement (eg, fewer stools, less blood in the stools, lower fever, improved appetite) is expected within one to two days if
         <em>
          Shigella
         </em>
         infection is treated with an antibiotic to which the isolate is susceptible [
         <a href="#rid57">
          57,78
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H672227011">
         <span class="h2">
          Treatment failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment failure is defined by persistent or worsening fever, grossly bloody stools, or unchanged stool frequency by Day 3 of therapy [
         <a href="#rid78">
          78
         </a>
         ]. Treatment failure suggests a resistant organism or other/additional pathogen. Stool cultures should be obtained in patients with treatment failure [
         <a href="#rid27">
          27,37
         </a>
         ]. Antibiotic therapy should be changed accordingly, based upon culture and susceptibility results. Consultation with an expert in infectious diseases may be warranted. Morbidity and mortality are increased in patients in whom the isolate is not susceptible to the initial antimicrobial agent [
         <a href="#rid79">
          79,80
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H848310476">
         <span class="h2">
          Test of cure
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is not routinely necessary to obtain stool cultures after appropriate antibiotic therapy in patients who recovered clinically. However, follow-up cultures may be necessary to prevent spread of infection in specific settings (eg, among food-handlers, child care attendees or staff members).
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          PREVENTION
         </span>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          General measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         General recommendations for the prevention of
         <em>
          Shigella
         </em>
         infections include the use of safe drinking water, chlorination of unreliable water sources, strict hand washing, and refrigeration and proper cooking of food. A meta-analysis of clinical studies suggested that hand washing with soap reduces the risk of shigellosis by 59 percent [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
         Breast feeding is strongly encouraged in young infants living in less-developed settings because it confers considerable protection against shigellosis, especially against moderate-to-severe disease [
         <a href="#rid82">
          82,83
         </a>
         ].
        </p>
        <p>
         Food handlers infected with
         <em>
          Shigella
         </em>
         must be treated with antibiotics and should not be involved in the preparation of food until their stool cultures are negative, which generally requires at least 48 hours of antibiotic treatment. (See
         <a class="local">
          'Indications'
         </a>
         above.)
        </p>
        <p>
         Persons infected with
         <em>
          Shigella
         </em>
         should stay out of recreational water (eg, swimming pools, water playgrounds, ponds, lakes) during diarrhea and for two weeks after it ends [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Isolation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to standard precautions, contact precautions are indicated for the duration of illness or hospitalization for
         <em>
          Shigella
         </em>
         infection [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">
          "Infection prevention: Precautions for preventing transmission of infection", section on 'Standard precautions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">
          "Infection prevention: Precautions for preventing transmission of infection", section on 'Contact precautions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          School or daycare
         </span>
         <span class="headingEndMark">
          —
         </span>
         If
         <em>
          Shigella
         </em>
         infection occurs in a child attending daycare or in a staff member, stool cultures or polymerase chain reaction (PCR) tests should be obtained from other symptomatic daycare attendees, staff members, and household contacts [
         <a href="#rid56">
          56
         </a>
         ]. The local health department should be contacted to assess and manage potential outbreaks.
        </p>
        <p>
         Symptomatic persons with positive stool cultures or PCR tests should be excluded from the child care center until appropriate antibiotic therapy is initiated and ≥24 hours after diarrhea has resolved and, depending upon local regulations, until one or more stool cultures or PCR tests are negative for
         <em>
          Shigella
         </em>
         . In an observational study that used published data to calculate the effectiveness of various policies for exclusion from childcare in the setting of a
         <em>
          Shigella
         </em>
         outbreak, requiring a single negative PCR test before returning to childcare was associated with the lowest probability of transmission [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
         Additional control measures for day schools and daycare centers include [
         <a href="#rid36">
          36,85-87
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Appropriate hand washing and diapering practices
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Scheduling hand washing sessions on arrival at the daycare center, before meals, or after playing outdoors
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Supervised hand washing for young children
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eliminating water play areas
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Vaccine
         </span>
         <span class="headingEndMark">
          —
         </span>
         A vaccine against shigellosis is not yet available, though this is an area of active investigation, based mainly on observations that serum antibodies against
         <em>
          Shigella
         </em>
         lipopolysaccharide antigens correlate with serotype-specific protection against shigellosis [
         <a href="#rid88">
          88-91
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Antibiotic prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         We generally do not suggest prophylactic antibiotics to prevent
         <em>
          Shigella
         </em>
         gastroenteritis in travelers unless the child has an underlying medical illness that predisposes them to severe consequences of shigellosis. The use of antibiotics, including
         <a class="drug drug_pediatric" data-topicid="94528" href="/z/d/drug information/94528.html" rel="external">
          rifaximin
         </a>
         (which is not absorbed), to prevent traveler's diarrhea is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/99648.html" rel="external">
          "Travelers' diarrhea: Treatment and prevention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H583353099">
         <span class="h1">
          MANDATED REPORTING
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States, laboratory-confirmed cases of shigellosis should be reported to the Centers for Disease Control and Prevention through local and state health departments [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3293689850">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110029.html" rel="external">
          "Society guideline links: Acute diarrhea in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive care
         </strong>
         – Correction of fluid and electrolyte losses is the mainstay of treatment for acute gastroenteritis in children, no matter the cause. (See
         <a class="medical medical_review" href="/z/d/html/6129.html" rel="external">
          "Oral rehydration therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6103.html" rel="external">
          "Treatment of hypovolemia (dehydration) in children in resource-abundant settings"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Avoid antimotility drugs (eg,
         <a class="drug drug_pediatric" data-topicid="12679" href="/z/d/drug information/12679.html" rel="external">
          paregoric
         </a>
         , diphenoxylate,
         <a class="drug drug_pediatric" data-topicid="12561" href="/z/d/drug information/12561.html" rel="external">
          loperamide
         </a>
         ) in children with suspected shigellosis because they may prolong symptoms and excretion of the organism. (See
         <a class="local">
          'Supportive therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Goals of antibiotic therapy
         </strong>
         – The goals of antibiotic therapy for
         <em>
          Shigella
         </em>
         include improvement in symptoms and eradication of the organism, which may decrease the spread of infection to contacts. (See
         <a class="local">
          'Rationale'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for antibiotic therapy
         </strong>
         – Decisions regarding initiation of antimicrobial therapy must consider the clinical condition of the patient, host factors that predispose to more severe infection, and public health considerations. (See
         <a class="local">
          'Indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Suspected shigellosis – Shigellosis should be suspected in children who present with bloody/mucous diarrhea, abdominal cramping, high fever, and polymorphonuclear leukocytes on a
         <a class="drug drug_pediatric" data-topicid="12599" href="/z/d/drug information/12599.html" rel="external">
          methylene blue
         </a>
         stain of the stool.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For children and adolescents with suspected shigellosis who are immunocompromised or who have clinical features suggestive of bacteremia (eg, leukocytosis, hypothermia, temperature &gt;39°C [102.2°F], lethargy), we recommend empiric antimicrobial therapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Culture-proven
         <em>
          Shigella
         </em>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For children and adolescents with symptomatic culture-prov
         <em>
          en Shigella
         </em>
         who have bacteremia, require hospitalization, attend daycare, live in institutions, or are involved in food handling, we recommend antimicrobial therapy (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). (See
         <a class="local">
          'Indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For symptomatic children and adolescents with culture-proven shigellosis or suspected shigellosis according to epidemiologic data or clinical presentation, we suggest antimicrobial therapy (
         <a class="grade" href="https:///uptodate/show/grade_4" rel="external">
          Grade 2A
         </a>
         ). (See
         <a class="local">
          'Indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of regimen
         </strong>
         – The empiric antimicrobial regimen is determined by host factors, severity of illness, local resistance patterns, and history of travel to an area of frequent resistance. Susceptibility testing guides changes in empiric therapy and should be performed on all isolates. (See
         <a class="local">
          'Choice of regimen'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We provide parenteral antimicrobial therapy for children with proven or suspected shigellosis and one or more of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Severe toxemia or suspected bacteremia
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Underlying immune deficiency
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Inability to take oral medications
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We typically use
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         as the first-line parenteral therapy for shigellosis in children &lt;18 years of age if the susceptibility of the isolate is unknown and extensively drug-resistant shigellosis is not suspected (
         <a class="graphic graphic_table graphicRef88651" href="/z/d/graphic/88651.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Parenteral versus oral therapy'
         </a>
         above and
         <a class="local">
          'Parenteral therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Oral treatment of shigellosis depends upon local resistance patterns.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We typically use
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         as the first-line oral treatment of shigellosis in children &lt;18 years of age if the antibiotic susceptibility of the isolate is unknown and extensively drug-resistant shigellosis is not suspected (
         <a class="graphic graphic_table graphicRef88651" href="/z/d/graphic/88651.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Oral therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The approach to the treatment of
         <em>
          Shigella
         </em>
         in adolescents ≥18 years is the same as that for adults. (See
         <a class="medical medical_review" href="/z/d/html/2701.html" rel="external">
          "Shigella infection: Treatment and prevention in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment failure
         </strong>
         – Treatment failure is defined by Persistent fever, grossly bloody stools, or unchanged stool frequency by day 3 of therapy. Treatment failure suggests a resistant organism or other/additional pathogen, and antibiotic therapy should be changed accordingly. (See
         <a class="local">
          'Treatment failure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          School and child care precautions
         </strong>
         – Symptomatic persons with stool cultures positive for
         <em>
          Shigella
         </em>
         should be excluded from daycare until treatment is initiated, the diarrhea has resolved, and, depending on local regulations, until stool cultures are negative for
         <em>
          Shigella
         </em>
         . (See
         <a class="local">
          'School or daycare'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ashkenazi S. Shigella infections in children: new insights. Semin Pediatr Infect Dis 2004; 15:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merzon E, Gutbir Y, Vinker S, et al. Early Childhood Shigellosis and Attention Deficit Hyperactivity Disorder: A Population-Based Cohort Study with a Prolonged Follow-up. J Atten Disord 2021; 25:1791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viner Y, Miron D, Gottfried E, et al. Neonatal shigellosis. Isr Med Assoc J 2001; 3:964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baer JT, Vugia DJ, Reingold AL, et al. HIV infection as a risk factor for shigellosis. Emerg Infect Dis 1999; 5:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angulo FJ, Swerdlow DL. Bacterial enteric infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 Suppl 1:S84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Struelens MJ, Patte D, Kabir I, et al. Shigella septicemia: prevalence, presentation, risk factors, and outcome. J Infect Dis 1985; 152:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg D, Marcu S, Melamed R, Lifshitz M. Shigella bacteremia: a retrospective study. Clin Pediatr (Phila) 2003; 42:411.
          </a>
         </li>
         <li class="breakAll">
          Ashkenazi S. Shigella species. In: Principles and Practice of Pediatric Infectious Diseases, 5th ed, Long SS, Prober CG, Fischer M (Eds), Elsevier, Philadelphia 2018. p.842.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guarino A, Ashkenazi S, Gendrel D, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr 2014; 59:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kabir I, Butler T, Underwood LE, Rahman MM. Effects of a protein-rich diet during convalescence from shigellosis on catch-up growth, serum proteins, and insulin-like growth factor-I. Pediatr Res 1992; 32:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kabir I, Rahman MM, Haider R, et al. Increased height gain of children fed a high-protein diet during convalescence from shigellosis: a six-month follow-Up study. J Nutr 1998; 128:1688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazumder RN, Hoque SS, Ashraf H, et al. Early feeding of an energy dense diet during acute shigellosis enhances growth in malnourished children. J Nutr 1997; 127:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hossain S, Biswas R, Kabir I, et al. Single dose vitamin A treatment in acute shigellosis in Bangladesh children: randomised double blind controlled trial. BMJ 1998; 316:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy SK, Raqib R, Khatun W, et al. Zinc supplementation in the management of shigellosis in malnourished children in Bangladesh. Eur J Clin Nutr 2008; 62:849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabbani GH, Ahmed S, Hossain I, et al. Green banana reduces clinical severity of childhood shigellosis: a double-blind, randomized, controlled clinical trial. Pediatr Infect Dis J 2009; 28:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabbani GH, Teka T, Zaman B, et al. Clinical studies in persistent diarrhea: dietary management with green banana or pectin in Bangladeshi children. Gastroenterology 2001; 121:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabbani GH, Teka T, Saha SK, et al. Green banana and pectin improve small intestinal permeability and reduce fluid loss in Bangladeshi children with persistent diarrhea. Dig Dis Sci 2004; 49:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotloff KL, Riddle MS, Platts-Mills JA, et al. Shigellosis. Lancet 2018; 391:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DuPont HL, Hornick RB. Adverse effect of lomotil therapy in shigellosis. JAMA 1973; 226:1525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kruse H, Kariuki S, Søli N, Olsvik O. Multiresistant Shigella species from African AIDS patients: antibacterial resistance patterns and application of the E-test for determination of minimum inhibitory concentration. Scand J Infect Dis 1992; 24:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashkenazi S, Levy I, Kazaronovski V, Samra Z. Growing antimicrobial resistance of Shigella isolates. J Antimicrob Chemother 2003; 51:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shiferaw B, Solghan S, Palmer A, et al. Antimicrobial susceptibility patterns of Shigella isolates in Foodborne Diseases Active Surveillance Network (FoodNet) sites, 2000-2010. Clin Infect Dis 2012; 54 Suppl 5:S458.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS). NARMS Now: Human data, Shigella, 2022. Available at: https://wwwn.cdc.gov/narmsnow/ (Accessed on March 01, 2023).
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Health Advisory.  Increase in Extensively Drug-Resistant Shigellosis in the United States. Available at: https://emergency.cdc.gov/han/2023/han00486.asp (Accessed on March 01, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong MR, Reddy V, Hanson H, et al. Antimicrobial resistance trends of Shigella serotypes in New York City, 2006-2009. Microb Drug Resist 2010; 16:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowen A, Hurd J, Hoover C, et al. Importation and domestic transmission of Shigella sonnei resistant to ciprofloxacin - United States, May 2014-February 2015. MMWR Morb Mortal Wkly Rep 2015; 64:318.
          </a>
         </li>
         <li class="breakAll">
          CDC recommendations for diagnosing and managing Shigella strains with possible reduced susceptibility to ciprofloxacin https://emergency.cdc.gov/han/han00401.asp (Accessed on April 19, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spellerberg B, Rabsch W, Pietsch M, et al. Extended-spectrum β-Lactamase Acquisition in Patients Receiving Systemic Cephalosporin Treatment for Salmonella spp. and Shigella spp. Infection. Clin Infect Dis 2020; 70:714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heiman KE, Karlsson M, Grass J, et al. Notes from the field: Shigella with decreased susceptibility to azithromycin among men who have sex with men - United States, 2002-2013. MMWR Morb Mortal Wkly Rep 2014; 63:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heiman KE, Grass JE, Sjölund-Karlsson M, Bowen A. Shigellosis with decreased susceptibility to azithromycin. Pediatr Infect Dis J 2014; 33:1204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howie RL, Folster JP, Bowen A, et al. Reduced azithromycin susceptibility in Shigella sonnei, United States. Microb Drug Resist 2010; 16:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sjölund Karlsson M, Bowen A, Reporter R, et al. Outbreak of infections caused by Shigella sonnei with reduced susceptibility to azithromycin in the United States. Antimicrob Agents Chemother 2013; 57:1559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowen A, Eikmeier D, Talley P, et al. Notes from the Field: Outbreaks of Shigella sonnei Infection with Decreased Susceptibility to Azithromycin Among Men Who Have Sex with Men - Chicago and Metropolitan Minneapolis-St. Paul, 2014. MMWR Morb Mortal Wkly Rep 2015; 64:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hines JZ, Pinsent T, Rees K, et al. Notes from the Field: Shigellosis Outbreak Among Men Who Have Sex with Men and Homeless Persons - Oregon, 2015-2016. MMWR Morb Mortal Wkly Rep 2016; 65:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray K, Reddy V, Kornblum JS, et al. Increasing Antibiotic Resistance in Shigella spp. from Infected New York City Residents, New York, USA. Emerg Infect Dis 2017; 23:332.
          </a>
         </li>
         <li class="breakAll">
          CDC Health Advisory. Ciprofloxacin- and Azithromycin-Nonsusceptible Shigellosis in the United States. http://emergency.cdc.gov/han/han00379.asp.
         </li>
         <li class="breakAll">
          CDC. Health Alert. Update -- CDC recommendations for managing and reporting Shigella infections with possible reduced susceptibility to ciprofloxacin. Available at: https://emergency.cdc.gov/han/han00411.asp (Accessed on June 11, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheasty T, Day M, Threlfall EJ. Increasing incidence of resistance to nalidixic acid in shigellas from humans in England and Wales: implications for therapy. Clin Microbiol Infect 2004; 10:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boumghar-Bourtchai L, Mariani-Kurkdjian P, Bingen E, et al. Macrolide-resistant Shigella sonnei. Emerg Infect Dis 2008; 14:1297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gu B, Zhou M, Ke X, et al. Comparison of resistance to third-generation cephalosporins in Shigella between Europe-America and Asia-Africa from 1998 to 2012. Epidemiol Infect 2015; 143:2687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heffernan H, Woodhouse R, Hewison C, Sherwood J. Antimicrobial resistance among Shigella in New Zealand. N Z Med J 2018; 131:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennish ML, Salam MA, Hossain MA, et al. Antimicrobial resistance of Shigella isolates in Bangladesh, 1983-1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, and nalidixic acid. Clin Infect Dis 1992; 14:1055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munshi MH, Sack DA, Haider K, et al. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet 1987; 2:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salam MA, Bennish ML. Antimicrobial therapy for shigellosis. Rev Infect Dis 1991; 13 Suppl 4:S332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahman M, Shoma S, Rashid H, et al. Increasing spectrum in antimicrobial resistance of Shigella isolates in Bangladesh: resistance to azithromycin and ceftriaxone and decreased susceptibility to ciprofloxacin. J Health Popul Nutr 2007; 25:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuo CY, Su LH, Perera J, et al. Antimicrobial susceptibility of Shigella isolates in eight Asian countries, 2001-2004. J Microbiol Immunol Infect 2008; 41:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Houpt ER, Ferdous T, Ara R, et al. Clinical Outcomes of Drug-resistant Shigellosis Treated With Azithromycin in Bangladesh. Clin Infect Dis 2021; 72:1793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haltalin KC, Nelson JD, Ring R 3rd, et al. Double-blind treatment study of shigellosis comparing ampicillin, sulfadiazine, and placebo. J Pediatr 1967; 70:970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haltalin KC, Kusmiesz HT, Hinton LV, Nelson JD. Treatment of acute diarrhea in outpatients. Double-blind study comparing ampicillin and placebo. Am J Dis Child 1972; 124:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia de Olarte D, Trujillo H, Agudelo N, et al. Treatment of diarrhea in malnourished infants and children. A double-blind study comparing ampicillin and placebo. Am J Dis Child 1974; 127:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson JD, Haltalin KC. Broad-spectrum penicillins in enteric infections of children. Ann N Y Acad Sci 1967; 145:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christopher PR, David KV, John SM, Sankarapandian V. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev 2010; :CD006784.
          </a>
         </li>
         <li class="breakAll">
          Ashkenazi S. Shigella species. In: Antimicrobial therapy and vaccines, 2nd ed, Yu VL, Weer R, Raoult D (Eds), Apple Tree Production, New York 2002. p.615.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennish ML, Khan WA, Begum M, et al. Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh. Clin Infect Dis 2006; 42:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DuPont HL, Levine MM, Hornick RB, Formal SB. Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis 1989; 159:1126.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Shigella Infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd Ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.668.
         </li>
         <li class="breakAll">
          World Health Organization. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1 http://whqlibdoc.who.int/publications/2005/9241592330.pdf (Accessed on March 21, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane CR, Sutton B, Valcanis M, et al. Travel Destinations and Sexual Behavior as Indicators of Antibiotic Resistant Shigella Strains--Victoria, Australia. Clin Infect Dis 2016; 62:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson MA, Schutze GE, COMMITTEE ON INFECTIOUS DISEASES. The Use of Systemic and Topical Fluoroquinolones. Pediatrics 2016; 138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lolekha S, Vibulbandhitkit S, Poonyarit P. Response to antimicrobial therapy for shigellosis in Thailand. Rev Infect Dis 1991; 13 Suppl 4:S342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salam MA, Dhar U, Khan WA, Bennish ML. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet 1998; 352:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eidlitz-Marcus T, Cohen YH, Nussinovitch M, et al. Comparative efficacy of two- and five-day courses of ceftriaxone for treatment of severe shigellosis in children. J Pediatr 1993; 123:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kabir I, Butler T, Khanam A. Comparative efficacies of single intravenous doses of ceftriaxone and ampicillin for shigellosis in a placebo-controlled trial. Antimicrob Agents Chemother 1986; 29:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan WA, Seas C, Dhar U, et al. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann Intern Med 1997; 126:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennish ML, Salam MA, Haider R, Barza M. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis 1990; 162:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varsano I, Eidlitz-Marcus T, Nussinovitch M, Elian I. Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children. J Pediatr 1991; 118:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charles H, Prochazka M, Thorley K, et al. Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021-22: a descriptive epidemiological study. Lancet Infect Dis 2022; 22:1503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Notes from the field: Outbreak of infections caused by Shigella sonnei with decreased susceptibility to azithromycin--Los Angeles, California, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashkenazi S, Amir J, Waisman Y, et al. A randomized, double-blind study comparing cefixime and trimethoprim-sulfamethoxazole in the treatment of childhood shigellosis. J Pediatr 1993; 123:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helvaci M, Bektaşlar D, Ozkaya B, et al. Comparative efficacy of cefixime and ampicillin-sulbactam in shigellosis in children. Acta Paediatr Jpn 1998; 40:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prado D, López E, Liu H, et al. Ceftibuten and trimethoprim-sulfamethoxazole for treatment of Shigella and enteroinvasive Escherichia coli disease. Pediatr Infect Dis J 1992; 11:644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basualdo W, Arbo A. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr Infect Dis J 2003; 22:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miron D, Torem M, Merom R, Colodner R. Azithromycin as an alternative to nalidixic acid in the therapy of childhood shigellosis. Pediatr Infect Dis J 2004; 23:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhattacharya K, Bhattacharya MK, Dutta D, et al. Double-blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children. Acta Paediatr 1997; 86:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogerie F, Ott D, Vandepitte J, et al. Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults. Antimicrob Agents Chemother 1986; 29:883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vinh H, Wain J, Chinh MT, et al. Treatment of bacillary dysentery in Vietnamese children: two doses of ofloxacin versus 5-days nalidixic acid. Trans R Soc Trop Med Hyg 2000; 94:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Traa BS, Walker CL, Munos M, Black RE. Antibiotics for the treatment of dysentery in children. Int J Epidemiol 2010; 39 Suppl 1:i70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Islam MR, Alam AN, Hussain MS, Mahalanabis D. Effect of antimicrobial (nalidixic acid) therapy in shigellosis and predictive values of outcome variables in patients susceptible or resistant to it. J Trop Med Hyg 1995; 98:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kagalwalla AF, Khan SN, Kagalwalla YA, et al. Childhood shigellosis in Saudi Arabia. Pediatr Infect Dis J 1992; 11:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennish ML, Salam MA, Wahed MA. Enteric protein loss during shigellosis. Am J Gastroenterol 1993; 88:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtis V, Cairncross S. Effect of washing hands with soap on diarrhoea risk in the community: a systematic review. Lancet Infect Dis 2003; 3:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed F, Clemens JD, Rao MR, et al. Community-based evaluation of the effect of breast-feeding on the risk of microbiologically confirmed or clinically presumptive shigellosis in Bangladeshi children. Pediatrics 1992; 90:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindsay B, Saha D, Sanogo D, et al. Association Between Shigella Infection and Diarrhea Varies Based on Location and Age of Children. Am J Trop Med Hyg 2015; 93:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carias C, Undurraga EA, Hurd J, et al. Evaluation of the impact of shigellosis exclusion policies in childcare settings upon detection of a shigellosis outbreak. BMC Infect Dis 2019; 19:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Outbreaks of multidrug-resistant Shigella sonnei gastroenteritis associated with day care centers--Kansas, Kentucky, and Missouri, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:1068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gangaros EJ. Annotation: a community-focused strategy for the control of day-care center shigellosis. Am J Public Health 1995; 85:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman RE, Shillam PJ. The use of hygiene, cohorting, and antimicrobial therapy to control an outbreak of shigellosis. Am J Dis Child 1990; 144:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahman KM, Arifeen SE, Zaman K, et al. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh. Vaccine 2011; 29:1347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Passwell JH, Ashkenzi S, Banet-Levi Y, et al. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine 2010; 28:2231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashkenazi S, Cohen D. An update on vaccines against Shigella. Ther Adv Vaccines 2013; 1:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen D, Meron-Sudai S, Bialik A, et al. Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis. Hum Vaccin Immunother 2019; 15:1401.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System. wwwn.cdc.gov/nndss/ (Accessed on March 06, 2013).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6003 Version 45.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15494948" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Shigella infections in children: new insights.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32698643" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Early Childhood Shigellosis and Attention Deficit Hyperactivity Disorder: A Population-Based Cohort Study with a Prolonged Follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11794928" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Neonatal shigellosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10603219" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : HIV infection as a risk factor for shigellosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8547518" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Bacterial enteric infections in persons infected with human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4045231" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Shigella septicemia: prevalence, presentation, risk factors, and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12862343" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Shigella bacteremia: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12862343" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Shigella bacteremia: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24739189" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1287560" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Effects of a protein-rich diet during convalescence from shigellosis on catch-up growth, serum proteins, and insulin-like growth factor-I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9772137" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Increased height gain of children fed a high-protein diet during convalescence from shigellosis: a six-month follow-Up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9040543" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Early feeding of an energy dense diet during acute shigellosis enhances growth in malnourished children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9492664" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Single dose vitamin A treatment in acute shigellosis in Bangladesh children: randomised double blind controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17554249" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Zinc supplementation in the management of shigellosis in malnourished children in Bangladesh.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19319017" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Green banana reduces clinical severity of childhood shigellosis: a double-blind, randomized, controlled clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11522739" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical studies in persistent diarrhea: dietary management with green banana or pectin in Bangladeshi children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15139502" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Green banana and pectin improve small intestinal permeability and reduce fluid loss in Bangladeshi children with persistent diarrhea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29254859" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Shigellosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4587313" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Adverse effect of lomotil therapy in shigellosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1287807" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Multiresistant Shigella species from African AIDS patients: antibacterial resistance patterns and application of the E-test for determination of minimum inhibitory concentration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12562716" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Growing antimicrobial resistance of Shigella isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22572670" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Antimicrobial susceptibility patterns of Shigella isolates in Foodborne Diseases Active Surveillance Network (FoodNet) sites, 2000-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22572670" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Antimicrobial susceptibility patterns of Shigella isolates in Foodborne Diseases Active Surveillance Network (FoodNet) sites, 2000-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22572670" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Antimicrobial susceptibility patterns of Shigella isolates in Foodborne Diseases Active Surveillance Network (FoodNet) sites, 2000-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20438349" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Antimicrobial resistance trends of Shigella serotypes in New York City, 2006-2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25837241" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Importation and domestic transmission of Shigella sonnei resistant to ciprofloxacin - United States, May 2014-February 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25837241" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Importation and domestic transmission of Shigella sonnei resistant to ciprofloxacin - United States, May 2014-February 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31165140" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Extended-spectrumβ-Lactamase Acquisition in Patients Receiving Systemic Cephalosporin Treatment for Salmonella spp. and Shigella spp. Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24522098" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Notes from the field: Shigella with decreased susceptibility to azithromycin among men who have sex with men - United States, 2002-2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25361413" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Shigellosis with decreased susceptibility to azithromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20624094" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Reduced azithromycin susceptibility in Shigella sonnei, United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23274665" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Outbreak of infections caused by Shigella sonnei with reduced susceptibility to azithromycin in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26042652" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Notes from the Field: Outbreaks of Shigella sonnei Infection with Decreased Susceptibility to Azithromycin Among Men Who Have Sex with Men - Chicago and Metropolitan Minneapolis-St. Paul, 2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27513523" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Notes from the Field: Shigellosis Outbreak Among Men Who Have Sex with Men and Homeless Persons - Oregon, 2015-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28098543" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Increasing Antibiotic Resistance in Shigella spp. from Infected New York City Residents, New York, USA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28098543" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Increasing Antibiotic Resistance in Shigella spp. from Infected New York City Residents, New York, USA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28098543" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Increasing Antibiotic Resistance in Shigella spp. from Infected New York City Residents, New York, USA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15522014" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Increasing incidence of resistance to nalidixic acid in shigellas from humans in England and Wales: implications for therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18680661" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Macrolide-resistant Shigella sonnei.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25553947" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Comparison of resistance to third-generation cephalosporins in Shigella between Europe-America and Asia-Africa from 1998 to 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29927916" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Antimicrobial resistance among Shigella in New Zealand.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1600006" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Antimicrobial resistance of Shigella isolates in Bangladesh, 1983-1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, and nalidixic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2887725" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2047659" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Antimicrobial therapy for shigellosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17985817" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Increasing spectrum in antimicrobial resistance of Shigella isolates in Bangladesh: resistance to azithromycin and ceftriaxone and decreased susceptibility to ciprofloxacin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18473096" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Antimicrobial susceptibility of Shigella isolates in eight Asian countries, 2001-2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32239137" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Clinical Outcomes of Drug-resistant Shigellosis Treated With Azithromycin in Bangladesh.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5338090" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Double-blind treatment study of shigellosis comparing ampicillin, sulfadiazine, and placebo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4562790" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Treatment of acute diarrhea in outpatients. Double-blind study comparing ampicillin and placebo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4592549" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Treatment of diarrhea in malnourished infants and children. A double-blind study comparing ampicillin and placebo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4935174" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Broad-spectrum penicillins in enteric infections of children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20687081" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Antibiotic therapy for Shigella dysentery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20687081" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Antibiotic therapy for Shigella dysentery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16392080" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2656880" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Inoculum size in shigellosis and implications for expected mode of transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2656880" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Inoculum size in shigellosis and implications for expected mode of transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2656880" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Inoculum size in shigellosis and implications for expected mode of transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26679624" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Travel Destinations and Sexual Behavior as Indicators of Antibiotic Resistant Shigella Strains--Victoria, Australia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27940800" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The Use of Systemic and Topical Fluoroquinolones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2047660" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Response to antimicrobial therapy for shigellosis in Thailand.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9716056" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8229499" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Comparative efficacy of two- and five-day courses of ceftriaxone for treatment of severe shigellosis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3518625" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Comparative efficacies of single intravenous doses of ceftriaxone and ampicillin for shigellosis in a placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9139555" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2201742" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2007941" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35809593" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021-22: a descriptive epidemiological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23466436" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Notes from the field: Outbreak of infections caused by Shigella sonnei with decreased susceptibility to azithromycin--Los Angeles, California, 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8229498" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : A randomized, double-blind study comparing cefixime and trimethoprim-sulfamethoxazole in the treatment of childhood shigellosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9581302" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Comparative efficacy of cefixime and ampicillin-sulbactam in shigellosis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1523076" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Ceftibuten and trimethoprim-sulfamethoxazole for treatment of Shigella and enteroinvasive Escherichia coli disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12712971" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15071299" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Azithromycin as an alternative to nalidixic acid in the therapy of childhood shigellosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9099325" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Double-blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3524434" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10975012" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Treatment of bacillary dysentery in Vietnamese children: two doses of ofloxacin versus 5-days nalidixic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20348130" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Antibiotics for the treatment of dysentery in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7714935" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Effect of antimicrobial (nalidixic acid) therapy in shigellosis and predictive values of outcome variables in patients susceptible or resistant to it.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1565538" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Childhood shigellosis in Saudi Arabia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8420274" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Enteric protein loss during shigellosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12726975" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Effect of washing hands with soap on diarrhoea risk in the community: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1518697" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Community-based evaluation of the effect of breast-feeding on the risk of microbiologically confirmed or clinically presumptive shigellosis in Bangladeshi children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26324734" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Association Between Shigella Infection and Diarrhea Varies Based on Location and Age of Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30782131" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Evaluation of the impact of shigellosis exclusion policies in childcare settings upon detection of a shigellosis outbreak.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17021592" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Outbreaks of multidrug-resistant Shigella sonnei gastroenteritis associated with day care centers--Kansas, Kentucky, and Missouri, 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7762706" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Annotation: a community-focused strategy for the control of day-care center shigellosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2405639" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : The use of hygiene, cohorting, and antimicrobial therapy to control an outbreak of shigellosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21040694" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20056180" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24757519" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : An update on vaccines against Shigella.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31070988" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
